Matthew J. Ahearne
YOU?
Author Swipe
View article: 326 | GLOFITAMAB AND EPCORITAMAB FOR LARGE B CELL LYMPHOMA IN 319 REAL WORLD PATIENTS: A RETROSPECTIVE UK ANALYSIS OF EFFICACY, TOLERABILITY AND PRACTICAL IMPLICATIONS
326 | GLOFITAMAB AND EPCORITAMAB FOR LARGE B CELL LYMPHOMA IN 319 REAL WORLD PATIENTS: A RETROSPECTIVE UK ANALYSIS OF EFFICACY, TOLERABILITY AND PRACTICAL IMPLICATIONS Open
View article: 40 | THE DIRECT STUDY: A ROADMAP FOR ctDNA‐BASED RISK PREDICTION, MOLECULAR PROFILING AND MRD DETECTION IN DIFFUSE LARGE B CELL LYMPHOMA
40 | THE DIRECT STUDY: A ROADMAP FOR ctDNA‐BASED RISK PREDICTION, MOLECULAR PROFILING AND MRD DETECTION IN DIFFUSE LARGE B CELL LYMPHOMA Open
View article: The DIRECT study: A roadmap for ctDNA-based risk prediction, molecular profiling and MRD detection in Diffuse Large B Cell Lymphoma
The DIRECT study: A roadmap for ctDNA-based risk prediction, molecular profiling and MRD detection in Diffuse Large B Cell Lymphoma Open
DIRECT was a prospective, multisite study assessing the feasibility and utility of circulating tumor DNA (ctDNA) in 188 patients with aggressive B-cell non-Hodgkin lymphoma using a lymphoma-customized assay and open-source pipeline. CtDNA …
View article: The chromosomal translocation <i>t</i> (1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to <i> <scp>RCC1</scp> :: <scp>IRF4</scp> </i> fusion
The chromosomal translocation <i>t</i> (1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to <i> <span>RCC1</span> :: <span>IRF4</span> </i> fusion Open
Summary The chromosomal translocation t (1;6)(p35.3;p25.2) is a rare but recurrent aberration in chronic lymphocytic leukaemia (CLL). We report molecular characterization of 10 cases and show that this translocation juxtaposes interferon r…
View article: Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphoma
Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphoma Open
To the Editor, Inhibitors of Bruton's tyrosine kinase (BTK) in chronic lymphocytic leukemia (CLL) result in durable responses in nearly all patients [1]. In contrast, in more aggressive B-cell malignancies, including diffuse large B cell l…
View article: Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial Open
BACKGROUND: The humoral and T-cell responses to booster COVID-19 vaccine types in multidisease immunocompromised individuals who do not generate adequate antibody responses to two COVID-19 vaccine doses, is not fully understood. The OCTAVE…
View article: Proliferative History Is a Novel Driver of Clinical Outcome in Splenic Marginal Zone Lymphoma
Proliferative History Is a Novel Driver of Clinical Outcome in Splenic Marginal Zone Lymphoma Open
The epiCMIT (epigenetically-determined Cumulative MIToses) mitotic clock traces B-cell mitotic history via DNA methylation changes in heterochromatin and H3K27me3-containing chromatin. While high scores correlated with poor outcomes in CLL…
View article: Dosage of high‐dose methotrexate as <scp>CNS</scp> prophylaxis in <scp>DLBCL: A</scp> detailed analysis of toxicity and impact on <scp>CNS</scp> relapse
Dosage of high‐dose methotrexate as <span>CNS</span> prophylaxis in <span>DLBCL: A</span> detailed analysis of toxicity and impact on <span>CNS</span> relapse Open
No abstract available.
View article: Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience Open
Bendamustine is among the most effective chemotherapeutics for indolent B-cell non-Hodgkin lymphomas (iNHL), but trial reports of significant toxicity, including opportunistic infections and excess deaths, led to prescriber warnings. We co…
View article: Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing
Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing Open
View article: A PHASE 1/2 STUDY OF STP938, A FIRST IN CLASS INHIBITOR OF CTP SYNTHASE 1, IN PATIENTS WITH RELAPSED/REFRACTORY B OR T CELL LYMPHOMA
A PHASE 1/2 STUDY OF STP938, A FIRST IN CLASS INHIBITOR OF CTP SYNTHASE 1, IN PATIENTS WITH RELAPSED/REFRACTORY B OR T CELL LYMPHOMA Open
Background: Chemotherapy-induced inhibition of DNA synthesis has proven efficacy in the treatment of lymphoma. Selective targeting of DNA synthesis has the potential to surpass this efficacy by maximizing pathway inhibition whilst avoiding…
View article: Predicting COVID‐19 infection risk in lymphoma by immune monitoring
Predicting COVID‐19 infection risk in lymphoma by immune monitoring Open
Introduction: patients with B-cell lymphoma have poorer antibody responses to COVID-19 vaccines compared to patients with other malignancies. However, the immune responses are heterogeneous and its association with clinical outcomes are po…
View article: Supplementary Figures 1 - 3 from Cap-Translation Inhibitor, 4EGI-1, Restores Sensitivity to ABT-737 Apoptosis through Cap-Dependent and -Independent Mechanisms in Chronic Lymphocytic Leukemia
Supplementary Figures 1 - 3 from Cap-Translation Inhibitor, 4EGI-1, Restores Sensitivity to ABT-737 Apoptosis through Cap-Dependent and -Independent Mechanisms in Chronic Lymphocytic Leukemia Open
PDF file - 665K, Supplemental Figure 1 Trace from a sucrose density gradient separation of lysates made from the MCF7 cell line. Supplemental Figure 2 BCL2 family protein expression in response to 4EGI-1 Supplemental Figure 3 Relative expr…
View article: Supplementary Figures 1 - 3 from Cap-Translation Inhibitor, 4EGI-1, Restores Sensitivity to ABT-737 Apoptosis through Cap-Dependent and -Independent Mechanisms in Chronic Lymphocytic Leukemia
Supplementary Figures 1 - 3 from Cap-Translation Inhibitor, 4EGI-1, Restores Sensitivity to ABT-737 Apoptosis through Cap-Dependent and -Independent Mechanisms in Chronic Lymphocytic Leukemia Open
PDF file - 665K, Supplemental Figure 1 Trace from a sucrose density gradient separation of lysates made from the MCF7 cell line. Supplemental Figure 2 BCL2 family protein expression in response to 4EGI-1 Supplemental Figure 3 Relative expr…
View article: Data from Cap-Translation Inhibitor, 4EGI-1, Restores Sensitivity to ABT-737 Apoptosis through Cap-Dependent and -Independent Mechanisms in Chronic Lymphocytic Leukemia
Data from Cap-Translation Inhibitor, 4EGI-1, Restores Sensitivity to ABT-737 Apoptosis through Cap-Dependent and -Independent Mechanisms in Chronic Lymphocytic Leukemia Open
Purpose: The lymph node microenvironment promotes resistance to chemotherapy in chronic lymphocytic leukemia (CLL), partly through induction of BCL2 family prosurvival proteins. Currently available inhibitors do not target all BCL2 …
View article: Data from Cap-Translation Inhibitor, 4EGI-1, Restores Sensitivity to ABT-737 Apoptosis through Cap-Dependent and -Independent Mechanisms in Chronic Lymphocytic Leukemia
Data from Cap-Translation Inhibitor, 4EGI-1, Restores Sensitivity to ABT-737 Apoptosis through Cap-Dependent and -Independent Mechanisms in Chronic Lymphocytic Leukemia Open
Purpose: The lymph node microenvironment promotes resistance to chemotherapy in chronic lymphocytic leukemia (CLL), partly through induction of BCL2 family prosurvival proteins. Currently available inhibitors do not target all BCL2 …
View article: Immunogenicity of SARSCoV2 Third Dose Vaccine Strategies in Immunocompromised Patients with Suboptimal Immunity Following Two Doses (OCTAVE-DUO): An Open-Label, Multi-Centre, Randomised, Controlled Phase III Trial
Immunogenicity of SARSCoV2 Third Dose Vaccine Strategies in Immunocompromised Patients with Suboptimal Immunity Following Two Doses (OCTAVE-DUO): An Open-Label, Multi-Centre, Randomised, Controlled Phase III Trial Open
View article: Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study Open
View article: Humoral and cellular responses to SARS-CoV-2 vaccination in patients with lymphoid malignancies
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with lymphoid malignancies Open
SUMMARY SARS-CoV-2 vaccination protects against COVID-19. Antibodies and antigen-specific T-cell responses against the spike domain can be used to measure vaccine immune response. Individuals with lymphoma have defects in humoral and cellu…
View article: Guidelines for the management of mature T‐ and natural killer‐cell lymphomas (excluding cutaneous T‐cell lymphoma): a British Society for Haematology Guideline
Guidelines for the management of mature T‐ and natural killer‐cell lymphomas (excluding cutaneous T‐cell lymphoma): a British Society for Haematology Guideline Open
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
View article: Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma
Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma Open
View article: Antibody Responses after SARS-CoV-2 Vaccination in Lymphoma
Antibody Responses after SARS-CoV-2 Vaccination in Lymphoma Open
Individuals with lymphoid malignancies have an increased mortality risk from COVID-19. Paradoxically, this population is least likely to be protected by SARS-CoV-2 vaccination as a result of disease- or treatment-related immunosuppression.…
View article: SEROLOGICAL RESPONSES AFTER SARS‐COV‐2 VACCINATION FIRST DOSE IN PATIENTS WITH LYMPHOID MALIGNANCY: FIRST INTERIM ANALYSIS OF THE UK PROSECO STUDY
SEROLOGICAL RESPONSES AFTER SARS‐COV‐2 VACCINATION FIRST DOSE IN PATIENTS WITH LYMPHOID MALIGNANCY: FIRST INTERIM ANALYSIS OF THE UK PROSECO STUDY Open
Introduction: A population-wide SARS-CoV-2 vaccination programme commenced in the UK in December 2020. Two vaccines have been widely deployed; BNT162b2 (Pfizer) and a ChAdOx1 nCoV-19 (Astra Zeneca) both encoding the full length of the spik…
View article: Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort
Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort Open
View article: Therapy-related leukaemias with balanced translocations can arise from pre-existing clonal haematopoiesis
Therapy-related leukaemias with balanced translocations can arise from pre-existing clonal haematopoiesis Open
View article: Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery Open
High-dose methotrexate (HD-MTX) is increasingly used as prophylaxis for patients with diffuse large B-cell lymphoma (DLBCL) at high risk of central nervous system (CNS) relapse. However, there is limited evidence to guide whether to interc…
View article: Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T-cell lymphoma
Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T-cell lymphoma Open
The mutational landscape of peripheral T-cell lymphoma (PTCL) is being revealed through sequencing of lymph node samples, but there has been little work on the mutational load that is present in cell-free DNA (cfDNA) from plasma. We report…
View article: The new biology of PTCL‐NOS and AITL: current status and future clinical impact
The new biology of PTCL‐NOS and AITL: current status and future clinical impact Open
Summary Peripheral T‐cell lymphomas (PTCL) comprise a heterogeneous group of aggressive lymphoproliferative disorders almost all of which are associated with poor clinical outcomes. Angioimmunoblastic T‐cell lymphoma (AITL) and some periph…
View article: Reconstruction of rearranged T‐cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T‐cell prolymphocytic leukemia
Reconstruction of rearranged T‐cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T‐cell prolymphocytic leukemia Open
T‐cell prolymphocytic leukemia (T‐PLL) is an aggressive tumor with leukemic presentation of mature T‐lymphocytes. Here, we aimed at characterizing the initial events in the molecular pathogenesis of T‐PLL and particularly, at determining t…
View article: Successful Treatment of Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type With Single-Agent Venetoclax
Successful Treatment of Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type With Single-Agent Venetoclax Open
Successful treatment of primary cutaneous diffuse large B cell lymphoma leg type with single agent venetoclax